R

Roche

Global pharmaceuticals and diagnostics company

Equipment Maintenance Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's
Shanghai, China
In Person
General Maintenance & RepairEquipment Maintenance

About the job

Requirements
  • A bachelor's degree or above in Mechanical Engineering, Electrical Engineering, Automation, Biopharmaceutical Engineering, or a related field.
  • Familiarity with relevant local regulations and authorities, such as NMPA.
  • At least 15 years of equipment maintenance experience in the injectable pharmaceutical industry; multinational biopharma experience is preferred.
  • At least 5 years of people management experience, with VACC leadership established.
  • Experience with strategic aseptic filling facility projects, including design, commissioning, and qualification.
  • Experience with new facility startup readiness and operational ramp-up, including organization, people, and operational management systems.
  • Expertise in mechanical systems, electrical systems, and automation and control.
  • Expertise in predictive maintenance, condition-based maintenance, preventive maintenance, and root cause analysis.
  • Experience with computerized maintenance management systems.
  • Ability to think strategically, translate strategies into actionable plans, and understand and apply agile ways of working.
  • Fluent English communication skills and the ability to communicate and collaborate effectively with team members and stakeholders.
Responsibilities
  • Manage, maintain, and optimize on-site equipment, including formulation, filling, packaging, and quality control laboratory equipment, to ensure efficient, controllable, and compliant production processes.
  • Support project and startup phases and liaise with the engineering firm on equipment design, construction, and qualification to ensure required standards and quality.
  • Lead the team to deliver the organization's vision and focus on strategic project development in China.
  • Support strategic project realization, including equipment design, qualification, operational readiness, and startup.
  • Collaborate with site and project organizations on process equipment, quality control laboratory equipment, warehouse equipment, and production shop-floor support.
  • Train site users in equipment operation and provide shop-floor service during production.
  • Implement site equipment management in accordance with global company strategy.
  • Lead, coach, and guide the organization; manage team members' performance and development to achieve organizational goals and support employee growth.
  • Build and retain an inclusive workforce and foster an environment that values diversity of thought and perspective.
  • Build and maintain partnerships with site leaders to align on strategic projects and day-to-day activities.
  • Manage daily safety, health, and environment activities; implement site procedures and programs; achieve site safety, health, and environment key performance indicators; and promote safety culture and behavior.
  • Build a talent pipeline and succession plans for key positions.
  • Promote continuous improvement and lean leadership principles, and maintain a culture of transparency, high performance, empowerment, and innovation.
  • Represent equipment in project design, construction, and qualification activities, including specification, sourcing, installation, and qualification, to support project delivery.
  • Establish and develop site equipment in alignment with company standards.
  • Assist the engineering head with team formation and hiring schedules to meet project and production ramp-up plans.
  • Develop team competencies through coaching, mentoring, training, and a skills development and appraisal program.
  • Represent equipment during regulatory inspections and audits and participate in responses to regulator and global quality audits.
  • Own production and laboratory equipment operation and maintenance in accordance with good manufacturing practice, environmental, health, and safety standards, and regulatory guidelines.
  • Improve production and laboratory operations through effective maintenance and operating programs, work prioritization, and compliance with operational, personnel, regulatory, and statutory requirements.
  • Plan maintenance activities with departments to ensure resources, parts, and vendors are available on schedule.
  • Execute preventive and corrective maintenance programs and equipment-specific maintenance plans to maximize availability and optimize lifecycle costs.
  • Maintain audit readiness by complying with standards and regulatory, statutory, and current good manufacturing practice requirements.
  • Ensure the quality and accuracy of equipment and maintenance data and records.
  • Participate in deviation investigations and corrective and preventive action execution, escalating as appropriate to ensure timely closure.
  • Drive continuous improvement through recommendations and initiatives that promote energy and water sustainability, safety, asset reliability, operational performance, operational excellence, and cost competitiveness.
  • Track, capture, and forward relevant information within the role's scope to the manager or department head in a timely manner.
  • Draft or review standard operating procedures and project and validation activities.
  • Record activities accurately and on time in accordance with company standards, and report events that are not aligned with standard operating procedures.
  • Apply incident, corrective and preventive action, and change-control processes.
  • Provide technical support in the filling area as a sterilization and aseptic expert.
  • Propose spare parts for responsible equipment and control costs within budget.
Desired Qualifications
  • Project Management Professional certification.
  • Multinational biopharma experience.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.